iconEarnings Announcement Before Market Open

Heron Therapeutics Inc HRTX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:28 AM EDT
3.12quote price arrow up+0.28 (+9.86%)
Volume
194,489
Close
2.84quote price arrow up+0.23 (+8.81%)
Volume
3,096,057
52 week range
0.50 - 3.22
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.84
  • 52 Week High3.22
  • 52 Week High Date03/13/24
  • 52 Week Low0.50
  • 52 Week Low Date11/09/23

Key Stats

  • Market Cap426.933M
  • Shares Out150.33M
  • 10 Day Average Volume2.56M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change67.06

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.84
  • 52 Week High3.22
  • 52 Week High Date03/13/24
  • 52 Week Low0.50
  • 52 Week Low Date11/09/23
  • Market Cap426.933M
  • Shares Out150.33M
  • 10 Day Average Volume2.56M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • YTD % Change67.06

RATIOS/PROFITABILITY

  • EPS (TTM)-0.87
  • P/E (TTM)-3.27
  • Fwd P/E (NTM)-10.60
  • EBITDA (TTM)-107.716M
  • ROE (TTM)-2,408.88%
  • Revenue (TTM)127.044M
  • Gross Margin (TTM)48.75%
  • Net Margin (TTM)-87.02%
  • Debt To Equity (MRQ)-440.03%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Heron Therapeutics Inc

 

Profile

MORE
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous...
Adam Morgan
Chairman of the Board
Craig Collard
Chief Executive Officer, Director
Ira Duarte
Chief Financial Officer, Principal Accounting Officer
William Forbes
Executive Vice President, Chief Development Officer
Lisa Peraza
Vice President
Address
4242 Campus Point Court, Suite 200
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
TRDA
Entrada Therapeutics Inc
13.50+0.34+2.58%
CDMO
Avid Bioservices Inc
8.42+0.17+2.06%
STRO
Sutro Biopharma Inc
3.89+0.06+1.57%
RIGL
Rigel Pharmaceuticals Inc
1.22+0.02+1.67%
NKTR
Nektar Therapeutics
1.65+0.08+5.10%